Targeting immunosupportive cancer therapies: Accentuate the positive, eliminate the negative Journal Article
| Authors: | Peggs, K. S.; Segal, N. H.; Allison, J. P. |
| Article Title: | Targeting immunosupportive cancer therapies: Accentuate the positive, eliminate the negative |
| Abstract: | In this Commentary we aim to provide an overview of some specific examples of cancer therapeutics, including targeted approaches using monoclonal antibodies and kinase inhibitors, as well as highlight novel approaches for enhancing immunological responses against tumors. We point out that a fundamental property of the cancer cell, genomic instability, confounds the targeted therapies that aim to induce cell death directly while simultaneously enhancing the potential for immunological attack by creating a large number of neoantigens. We argue for combinatorial strategies with agents that target tumor cells to release these antigens together with innovative therapies that enhance immunological responses by interfering with inhibitory checkpoints. © 2007 Elsevier Inc. All rights reserved. |
| Keywords: | cancer chemotherapy; treatment failure; gene mutation; sequence analysis; clinical trial; cytotoxic agent; cancer risk; monotherapy; nonhuman; unspecified side effect; cancer radiotherapy; rituximab; antineoplastic agent; neoplasms; t lymphocyte; t-lymphocytes; cell death; cell survival; imatinib; apoptosis; bone marrow suppression; epidermal growth factor receptor; epidermal growth factor receptor 2; combination chemotherapy; stem cell transplantation; protein tyrosine kinase; chronic myeloid leukemia; cetuximab; tumor antigen; cancer therapy; kidney carcinoma; monoclonal antibody; panitumumab; drug dose escalation; cd20 antigen; antibodies, monoclonal; immune response; immunotherapy; cancer vaccine; drug mechanism; genomic instability; cancer cell; tumor necrosis factor related apoptosis inducing ligand; ovary carcinoma; target cell; tumor necrosis factor receptor; trastuzumab; cytotoxic t lymphocyte antigen 4; phosphotransferase inhibitor; pertuzumab; denileukin diftitox; models, immunological; bone marrow cancer |
| Journal Title: | Cancer Cell |
| Volume: | 12 |
| Issue: | 3 |
| ISSN: | 1535-6108 |
| Publisher: | Cell Press |
| Date Published: | 2007-09-01 |
| Start Page: | 192 |
| End Page: | 199 |
| Language: | English |
| DOI: | 10.1016/j.ccr.2007.08.023 |
| PUBMED: | 17785201 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 18" - "Export Date: 17 November 2011" - "CODEN: CCAEC" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work